Price
No data yet.
Social Signal Score
Analyst Ratings
49 analystsRevenue
$2.74B-7.44%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Viehbacher
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 7,500
- Beta
- 0.17
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.94
Financials
Revenue
$2.74B-7.4%Net Income
$97.50M-90.6%EBITDA
$78.20M-95.2%Free Cash Flow
$489.80M-30.6%EPS (diluted)
$0.66-86.0%Shares Outstanding (diluted)
148.70M-32.2%Operating Expenses
$1.21BCash & Debt
$1.28BReturn of Capital
$0.00Revenue by Segment (annual)
$9.62BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.81B | $1.29B | $8.85 |
| 2024 | $9.68B | $1.63B | $11.20 |
| 2023 | $9.84B | $1.16B | $8.02 |
| 2022 | $10.17B | $3.05B | $20.97 |
| 2021 | $10.98B | $1.56B | $10.44 |
| 2020 | $13.44B | $4.00B | $24.86 |
| 2019 | $14.38B | $5.89B | $31.47 |
| 2018 | $13.45B | $4.43B | $21.62 |
| 2017 | $12.27B | $2.54B | $11.94 |
| 2016 | $11.45B | $3.70B | $16.96 |
| 2015 | $10.76B | $3.55B | $15.38 |
| 2014 | $9.70B | $2.93B | $12.42 |
| 2013 | $6.93B | $1.86B | $7.86 |
| 2012 | $5.51B | $1.38B | $5.80 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BIIB's reported EPS growth of 3.3% a year over 13 years.
- EPS in 5 years
- $10.37
- Implied price
- $207.41
- Return from $219.88
- -1.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $103.12 — -53.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -6.7% | -16.9% | -13.6% | -10.7% | -8.2% | -5.9% |
| -1.7% | -12.4% | -9.0% | -5.9% | -3.3% | -0.9% |
| 3.3% | -8.0% | -4.3% | -1.2% | 1.6% | 4.2% |
| 8.3% | -3.5% | 0.3% | 3.6% | 6.6% | 9.2% |
| 13.3% | 0.9% | 4.9% | 8.4% | 11.5% | 14.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
160+337.35%Social Signal Score
Mentions (17)
- News (Marketaux)gurufocus.com·3d ago·Positive
Biogen's Litifilimab Phase 2 Data Shows Progress in Lupus Treatment, BIIB Stock Nears Fair Valuation On October 02, 2026, Biogen <em[+325 characters]
View source ↗ - Newsglobenewswire.com·3d ago·Positive
…udy, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest da…
View source ↗ - Newszacks.com·7d ago·Negative
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…on in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Soc…
View source ↗ - Newsmarketbeat.com·21d ago·Negative
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quarter and said its recently acquired assets could help accelerate revenue growth.
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology Biogen NASDAQ: BIIB executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines –
View source ↗ - News (RSS)yahoo·34d ago·Neutral
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
View source ↗ - Newsglobenewswire.com·35d ago·Negative
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
View source ↗ - News (RSS)investing·41d ago·Neutral
Biogen commits to Veeva Vault CRM platform globally
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)
View source ↗ - Newsprnewswire.com·43d ago·Neutral
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewswire/ -- Eisai Co., Ltd.
View source ↗ - Newszacks.com·46d ago·Negative
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $2.03 per share
Typical surprise +22.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$3.60 vs $2.94beat
- Wed, Apr 29$3.57 vs $3.05beat
- Fri, Feb 6$1.99 vs $1.63beat
- Thu, Oct 30$4.81 vs $3.88beat
- Thu, Jul 31$5.47 vs $3.90beat
- Thu, May 1$3.02 vs $2.90beat
Estimates and results for BIIB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIIB officers and directors.
- Bought
- $585
- Sold
- $771k
1 trade
3 trades
- Minor Lloydsold
- Minor Lloydsold
- Murphy Nicolebought
- Singhal Priyasold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 2, 2026 (15d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jul 8, 2026 (36d later)Sell$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 3, 2026 (28d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jun 9, 2026 (29d later)Buy$50,001 - $100,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jun 9, 2026 (28d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Jun 9, 2026 (29d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 13, 2026 (14d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (16d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (11d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.